Phase I/II Study Combining Humanised Anti-CD20 (Veltuzumab), Anti-CD22 (Epratuzumab) and Both Monoclonal Antibodies With Intensive Chemotherapy in Adults With Recurrent or Refractory B-precursor Acute Lymphoblastic Leukaemia (ALL).

Trial Profile

Phase I/II Study Combining Humanised Anti-CD20 (Veltuzumab), Anti-CD22 (Epratuzumab) and Both Monoclonal Antibodies With Intensive Chemotherapy in Adults With Recurrent or Refractory B-precursor Acute Lymphoblastic Leukaemia (ALL).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2016

At a glance

  • Drugs Epratuzumab (Primary) ; Veltuzumab (Primary) ; Asparaginase; Asparaginase; Daunorubicin; Dexamethasone; Methotrexate; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MARALL
  • Most Recent Events

    • 19 Oct 2014 Accrual to date is 100% according to United Kingdom Clinical Research Network record.
    • 19 Oct 2014 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
    • 11 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top